Article Per Year (5 Year)
p-Index From 2020 - 2025
0.23
P-Index
This Author published in this journals
All Journal Jurnal Implementa Husada
Hendra H
Puskesmas
Health Professions Medicine & Pharmacology Nursing Public Health Veterinary

Published : 1 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 1 Documents
Search

 1 
COVID-19: Terapi Penghambat IL-1 dan IL-6 Hendra H
JURNAL IMPLEMENTA HUSADA Vol 2, No 1 (2021)
Publisher : UMSU

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.30596/jih.v2i1.6338

Abstract

Abstract: As of February 2021, there are 102,817,575 cases of COVID-19 globally, causing 2,227,420 deaths, and has been declared as pandemic by WHO. Over time, the management of COVID-19 has evolved, namely the use of Interleukin (IL). Patients with severe COVID-19 experience a hyper-inflammatory response to the virus, called "cytokine storms". Cytokine storms are thought to occur due to the excessive release of pro-inflammatory cytokines such as IL-1β, IL-6, IL-18 and interferon-γ. In hyperinflammatory conditions, therapy with cytokine-blocking agents such as IL-1 inhibitors (Anakinra) and IL-6 inhibitors (Tocilizumab) is quite promising. Anakinra has the effect of lowering il-6 production, its because IL-1 is a potential inducer for IL-6, so the Tocilizumab effect is also seen in Anakinra. Anakinra has a short half-life, so the undesirable effect can stop immediately. However, interleukin therapy still requires further research related to the efficacy and safety of the drug.Keywords: COVID-19, IL-1 inhibitor, IL-6 inhibitor, Anakinra ,Tocilizumab
Co-Authors